{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated-interferon+alfa+2a&page=7", "query": { "intervention": "Pegylated-interferon alfa 2a", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 202, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated-interferon+alfa+2a&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated-interferon+alfa+2a&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T12:54:59.242Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00093093", "title": "Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Viramidine", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "pegylated interferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 900, "start_date": "2004-06", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2012-06-22", "last_synced_at": "2026-10-10T12:54:59.242Z", "location_count": 53, "location_summary": "Tucson, Arizona • Fresno, California • Los Angeles, California + 42 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093093" }, { "nct_id": "NCT01087944", "title": "A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Autoinjector", "type": "DEVICE" }, { "name": "Pre-filled syringe", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2010-03", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2016-02-09", "last_synced_at": "2026-10-10T12:54:59.242Z", "location_count": 12, "location_summary": "Los Angeles, California • Bradenton, Florida • Orlando, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Framingham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087944" }, { "nct_id": "NCT01030432", "title": "Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "BMS-650032", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 285, "start_date": "2010-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-10-10T12:54:59.242Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Orlando, Florida + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030432" }, { "nct_id": "NCT01392170", "title": "Pegasys in Patients With Chronic Myeloid Leukemia (CML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "PEG-IFNá-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 2, "start_date": "2011-10", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-05-04", "last_synced_at": "2026-10-10T12:54:59.242Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01392170" }, { "nct_id": "NCT01467492", "title": "Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 121, "start_date": "2012-01", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-08-03", "last_synced_at": "2026-10-10T12:54:59.242Z", "location_count": 27, "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01467492" }, { "nct_id": "NCT00926614", "title": "Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis c" ], "interventions": [ { "name": "pioglitazone (Actos)", "type": "DRUG" }, { "name": "atorvastatin (Lipitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brooke Army Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2008-09", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2012-02-14", "last_synced_at": "2026-10-10T12:54:59.242Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00926614" }, { "nct_id": "NCT01183169", "title": "Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 459, "start_date": "2010-08", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2016-08-25", "last_synced_at": "2026-10-10T12:54:59.242Z", "location_count": 18, "location_summary": "San Diego, California • Ventura, California • Bradenton, Florida + 13 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183169" }, { "nct_id": "NCT00402428", "title": "Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "albumin interferon alfa-2b", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Human Genome Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1331, "start_date": "2006-12", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2013-08-08", "last_synced_at": "2026-10-10T12:54:59.242Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402428" }, { "nct_id": "NCT00962871", "title": "A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis B, Chronic" ], "interventions": [ { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 30, "start_date": "2009-08", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-10-10T12:54:59.242Z", "location_count": 2, "location_summary": "Los Angeles, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00962871" }, { "nct_id": "NCT06079879", "title": "A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Essential Thrombocythemia" ], "interventions": [ { "name": "Bomedemstat", "type": "DRUG" }, { "name": "Anagrelide", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2023-12-31", "completion_date": "2028-08-18", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-10T12:54:59.242Z", "location_count": 15, "location_summary": "Glendale, Arizona • Glendale, California • Stanford, California + 12 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06079879" } ] }